Merus NV Reports Q2 2025 Revenue Increase of $1.5 Million, Driven by Higher Collaboration Sales
I'm PortAI, I can summarize articles.
Merus N.V. reported a $1.5 million revenue increase in Q2 2025, driven by higher collaboration sales with Incyte, PTx, and Gilead. For the first half of 2025, collaboration revenue reached $22 million, up from $15.2 million in 2024. The company also generated $13.3 million in commercial material revenue. As of June 30, 2025, Merus had $892 million in cash and equivalents, expected to fund operations until at least 2028. Promising Phase II study results for Petosemtamab showed a 63% response rate in treating PD-L1-positive head and neck cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments